FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average	burden										
hours per response	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar Ring C  (Last) C/O NUI	- N1	2. Issuer Name and Ticker or Trading Symbol  Nurix Therapeutics, Inc. [ NRIX ]  3. Date of Earliest Transaction (Month/Day/Year) 09/10/2021								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  General Counsel									
(Street) SAN FRANCI	sco C	A state)	-	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person										on					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y)				ion	2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an		(A) or		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 09/10/20				021	21			<b>M</b> <sup>(1)</sup>		2,000	A	\$1.8	86	3,	,286		D		
Common Stock 09/10/202					021	21		S <sup>(1)</sup>		700	D	\$35.09	71 <sup>(2)</sup>	2,	,586		D		
Common Stock 09/10/202					021	:1		S <sup>(1)</sup>		500	D	\$35.76	'684 <sup>(3)</sup> 2		2,086		D		
Common	Stock			09/10/2	021				S <sup>(1)</sup>		800	D	\$36.	76	5 1,286 D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed tion Date,	4. Transa Code ( 8)	action Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		Expiration	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. De Se (In	Price of rivative curity str. 5)	ivative derivative urity Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to	\$1.86	09/10/2021			M <sup>(1)</sup>	V	(A)	2,000	Exerci (4		09/30/2029	Common Stock	2,00		\$0.00	105,66	6	D	

## Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- 2. Represents the weighted average sale price. The lowest price at which shares were sold was \$34.58 and the highest price at which shares were sold was \$35.53. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- 3. Represents the weighted average sale price. The lowest price at which shares were sold was \$35.64 and the highest price at which shares were sold was \$35.90.
- 4. The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

## Remarks:

/s/ Christine Ring

09/13/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.